Revance Announces First Patient Enrolled for DaxibotulinumtoxinA in Glabellar Lines and Cervical Dystonia in China by Fosun Pharma

Under the license agreement, Fosun Pharma Industrial is responsible for conducting necessary clinical studies, marketing and sales in the Territory, while Revance is responsible for manufacturing drug substance and finished drug product for Fosun Pharma Industrial\xe2\x80\x99s clinical and commercial activities.